Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBE-vaccine Efficacy in RA Patients on Immunosuppressants
NCT01131910Phase 2Completed
- Sponsor
- Region Sörmland
- Start
- May 2010
- Primary completion
- May 2011
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE), sponsored by Region Sörmland. Primary endpoint: Seroconversion rate at 1 year. Started May 2010; status: completed.
02
Drugs
Tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT01131910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131910.